Patent · US Active

KRAS G12C inhibitors and methods of using the same

US11905281B2 · kind B2 · utility

8Cited by
63References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 24, 2020
Grant dateFeb 20, 2024
Priority date
Expiry dateJun 11, 2041

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D513/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.